Gilead Sciences Stock Analysis
GILD Stock | USD 73.01 0.60 0.83% |
Gilead Sciences is overvalued with Real Value of 70.09 and Target Price of 85.47. The main objective of Gilead Sciences stock analysis is to determine its intrinsic value, which is an estimate of what Gilead Sciences is worth, separate from its market price. There are two main types of Gilead Sciences' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Gilead Sciences' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Gilead Sciences' stock to identify patterns and trends that may indicate its future price movements.
The Gilead Sciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Gilead Sciences is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Gilead Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Gilead Sciences' ongoing operational relationships across important fundamental and technical indicators.
Gilead |
Gilead Stock Analysis Notes
About 89.0% of the company shares are owned by institutional investors. The book value of Gilead Sciences was currently reported as 18.33. The company has Price/Earnings To Growth (PEG) ratio of 0.45. Gilead Sciences last dividend was issued on the 14th of March 2024. The entity had 2:1 split on the 28th of January 2013. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 14400 people. To learn more about Gilead Sciences call John Martin at 650 574 3000 or check out https://www.gilead.com.Gilead Sciences Quarterly Total Revenue |
|
Gilead Sciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Gilead Sciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Gilead Sciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Gilead Sciences generated a negative expected return over the last 90 days | |
Over 89.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Acquisition by Andrew Dickinson of 3025 shares of Gilead Sciences subject to Rule 16b-3 |
Gilead Sciences Upcoming and Recent Events
Earnings reports are used by Gilead Sciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gilead Sciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Gilead Largest EPS Surprises
Earnings surprises can significantly impact Gilead Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2000-04-27 | 2000-03-31 | -0.01 | -0.0041 | 0.0059 | 59 | ||
2000-07-27 | 2000-06-30 | -0.01 | -0.0029 | 0.0071 | 71 | ||
2002-04-30 | 2002-03-31 | -0.01 | -0.0025 | 0.0075 | 75 |
Gilead Sciences Thematic Classifications
In addition to having Gilead Sciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Macroaxis IndexMacroaxis power theme of selected equities with solid fundamentals | ||
Corona OpportunityCoronavirus related entities to consider during and after the outbreak |
Gilead Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gilead Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gilead Sciences backward and forwards among themselves. Gilead Sciences' institutional investor refers to the entity that pools money to purchase Gilead Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Norges Bank | 2023-12-31 | 16.1 M | Bank Of New York Mellon Corp | 2023-12-31 | 15.5 M | Northern Trust Corp | 2023-12-31 | 14 M | Legal & General Group Plc | 2023-12-31 | 12.5 M | Parnassus Investments, Llc | 2023-12-31 | 12 M | Amvescap Plc. | 2023-12-31 | 11.6 M | Nuveen Asset Management, Llc | 2023-12-31 | 11.5 M | Royal Bank Of Canada | 2023-12-31 | 10.6 M | Amundi | 2023-12-31 | 10.5 M | Blackrock Inc | 2023-12-31 | 122.8 M | Vanguard Group Inc | 2023-12-31 | 111.8 M |
Gilead Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 90.21 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gilead Sciences's market, we take the total number of its shares issued and multiply it by Gilead Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Gilead Profitablity
Gilead Sciences' profitability indicators refer to fundamental financial ratios that showcase Gilead Sciences' ability to generate income relative to its revenue or operating costs. If, let's say, Gilead Sciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Gilead Sciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Gilead Sciences' profitability requires more research than a typical breakdown of Gilead Sciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42. Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.18 | 0.19 | |
Return On Assets | 0.09 | 0.1 | |
Return On Equity | 0.25 | 0.26 |
Management Efficiency
Gilead Sciences has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.19. The current year's Return On Assets is expected to grow to 0.1. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.Last Reported | Projected for 2024 | ||
Price Book Value Ratio | 4.44 | 7.85 | |
Enterprise Value Multiple | 10.26 | 10.77 | |
Price Fair Value | 4.44 | 7.85 |
The analysis of Gilead Sciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Gilead Sciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Gilead Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield 0.0425 | Forward Dividend Yield 0.0425 | Forward Dividend Rate 3.08 | Beta 0.2 |
Technical Drivers
As of the 28th of March, Gilead Sciences retains the Standard Deviation of 1.7, risk adjusted performance of (0.02), and Market Risk Adjusted Performance of (1.83). Gilead Sciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Gilead Sciences, which can be compared to its competitors. Please check out Gilead Sciences standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and potential upside to decide if Gilead Sciences is priced fairly, providing market reflects its last-minute price of 73.01 per share. Given that Gilead Sciences has information ratio of (0.13), we strongly advise you to confirm Gilead Sciences's regular market performance to make sure the company can sustain itself at a future point.Gilead Sciences Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Gilead Sciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Gilead Sciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Gilead Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gilead Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kevin Young over three months ago Acquisition by Kevin Young of 26000 shares of Gilead Sciences subject to Rule 16b-3 |
Gilead Sciences Outstanding Bonds
Gilead Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gilead Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gilead bonds can be classified according to their maturity, which is the date when Gilead Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
GILEAD SCIENCES INC Corp BondUS375558AW38 | View | |
GILEAD SCIENCES INC Corp BondUS375558AX11 | View | |
GILEAD SCIENCES INC Corp BondUS375558AZ68 | View | |
GILEAD SCIENCES INC Corp BondUS375558AS26 | View | |
GILEAD SCIENCES INC Corp BondUS375558BK80 | View | |
GILEAD SCIENCES INC Corp BondUS375558BJ18 | View | |
GILEAD SCIENCES INC Corp BondUS375558BM47 | View | |
GILEAD SCIENCES INC Corp BondUS375558BA09 | View |
Gilead Sciences Predictive Daily Indicators
Gilead Sciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gilead Sciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Gilead Sciences Corporate Filings
22nd of March 2024 Other Reports | ViewVerify | |
20th of March 2024 Other Reports | ViewVerify | |
18th of March 2024 Other Reports | ViewVerify | |
15th of March 2024 Other Reports | ViewVerify | |
8K | 14th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
11th of March 2024 Other Reports | ViewVerify | |
F4 | 29th of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Gilead Sciences Forecast Models
Gilead Sciences' time-series forecasting models are one of many Gilead Sciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gilead Sciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Gilead Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Gilead Sciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Gilead shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Gilead Sciences. By using and applying Gilead Stock analysis, traders can create a robust methodology for identifying Gilead entry and exit points for their positions.
Last Reported | Projected for 2024 | ||
Pretax Profit Margin | 0.25 | 0.27 | |
Operating Profit Margin | 0.35 | 0.36 | |
Net Profit Margin | 0.21 | 0.22 | |
Gross Profit Margin | 0.78 | 1.07 |
Current Gilead Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Gilead analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Gilead analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
85.47 | Buy | 31 | Odds |
Most Gilead analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Gilead stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Gilead Sciences, talking to its executives and customers, or listening to Gilead conference calls.
Gilead Stock Analysis Indicators
Gilead Sciences stock analysis indicators help investors evaluate how Gilead Sciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Gilead Sciences shares will generate the highest return on investment. By understating and applying Gilead Sciences stock analysis, traders can identify Gilead Sciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 5.4 B | |
Total Stockholder Equity | 22.7 B | |
Property Plant And Equipment Net | 5.3 B | |
Cash And Short Term Investments | 8.4 B | |
Cash | 6.1 B | |
50 Day M A | 75.6718 | |
Net Interest Income | -918 M | |
Total Current Liabilities | 11.3 B | |
Forward Price Earnings | 10.2564 | |
Investments | -1.9 B | |
Interest Expense | 944 M | |
Stock Based Compensation | 766 M | |
Long Term Debt | 23.2 B | |
Common Stock Shares Outstanding | 1.3 B | |
Tax Provision | 1.4 B | |
Quarterly Earnings Growth Y O Y | -0.131 | |
Other Current Assets | 2.4 B | |
Accounts Payable | 550 M | |
Net Debt | 18.9 B | |
Other Operating Expenses | 19.5 B | |
Non Current Assets Total | 45.7 B | |
Liabilities And Stockholders Equity | 62.1 B | |
Non Currrent Assets Other | 5.6 B |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.